Zobrazeno 1 - 10
of 1 289
pro vyhledávání: ''
Autor:
Hirotaka Matsumoto, Yoshihiko Taniguchi, Shunsuke Teraoka, Kenji Nagata, Asuka Okada, Daisuke Arai, Fujimoto Daichi, Go Saito, Eisaku Miyauchi, Toshihide Yokoyama, Hidekazu Suzuki, Takeshi Uenami, Yoshihiko Sakata, Takayuki Niitsu, Hayato Kawachi, Takashi Yokoi, Yuko Oya, Masaki Kokubo, Shunichiro Iwasawa
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 161
The incidence of real-world pneumonitis and durvalumab rechallenge during chemoradiotherapy and durvalumab consolidation for non-small cell lung cancer is unknown.We retrospectively evaluated the medical records of 302 consecutive patients diagnosed
Autor:
Junji Uchino, Akira Nakao, Osamu Hiranuma, Yusuke Chihara, Masahiro Iwasaku, Takashi Kijima, Chieko Takumi, Yoshiko Kaneko, Takahiro Yamada, Masafumi Takeshita, Makoto Hibino, Yoshie Morimoto, Koichi Takayama, Kenji Morimoto, Takayuki Takeda, Tadaaki Yamada, Yasuhiro Goto, Hiroyuki Yamaguchi, Takashi Yokoi
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 161
Combination therapy of immune checkpoint inhibitors and chemotherapy is considered to be one of the standard treatment options for patients with advanced non-small-cell lung cancer (NSCLC). However, the clinical significance of immune checkpoint inhi
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 158
Objectives The aim of this study was to investigate the risk of TB in advanced non-small cell lung cancer (NSCLC) patients treated with Immune checkpoint inhibitors (ICI) after a platinum-based chemotherapy. Materials and methods A nationwide populat
Autor:
S.F. Nyaw, T.H. So, K.O. Lam, T.C. Lam, C.L. Chiang, V.H. Lee, K.C. Tsang, F. Lim, Winnie Wai Lan Chan, F.M. Kong, A.W. Lee, J. Chik, H.C. Choi, J.O. Lau
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 159
Acquired resistance to TKI is an important unmet need in the management of EGFR mutated lung cancer. Recent clinical trial IMPower150 suggested that combination approach with VEGF inhibitor, check point inhibitor immunotherapy and platinum-based chem
Autor:
Vanathi Sivasubramaniam, Michael Boyer, Rina Hui, Jia Liu, Prunella Blinman, Jenny H. Lee, Nick Pavlakis, Stephen Clarke, Anthony J. Gill, Steven Kao, Winny Varikatt, Wendy A Cooper, Malinda Itchins, Megan B Barnet, Madhawa De Silva, Bo Gao, Alexander E. Davis, Adnan Nagrial, Kenneth Lee
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 155
Predictive biomarkers for poor response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is an area of ongoing research. This multicentre retrospective study sought to determine the impact of programmed death-ligand 1 (PD-
Autor:
Masahiro Tsuboi, Tomohiro Murakawa, Morihito Okada, Masayuki Chida, Kenji Suzuki, Kenichi Yoshimura, Yoichi Ohtaki, Tetsuya Mitsudomi, Hiroyuki Suzuki, Motoshi Takao, Hiroyuki Ito, Kimihiro Shimizu
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 153
Objectives The prognostic impact of surgical intervention for recurrent or residual non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement after tyrosine-kinase
Autor:
Maximilian Hochmair, A. Poltoratskiy, Michael Schumacher, Rafal Dziadziuszko, Silvia Novello, Konstantin Laktionov, Inna Egorova, Maria Rita Migliorino, Filippo de Marinis, W. Tang, Daphne Tsoi, Simona Rizzato, Gyula Ostoros, Antonio Passaro, L. Clementi, Agnieszka Cseh, Guzel Z Mukhametshina, Giulio Metro, Dariusz M. Kowalski, Maya Gottfried
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 152
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable treatment option for patients with epidermal growth factor receptor mutation-positive (EGFRm +) non-small cell lung cancer (NSCLC). However, such studies often excl
Autor:
Hidetoshi Kasuya, Bierta E. Barfod, Toru Serizawa, Yasunori Sato, Masaaki Yamamoto, Yoshinori Higuchi
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 149
There is little information on stereotactic radiosurgery (SRS) results for brain metastases (BMs) in lung cancer patients ≥75 years of age. We aimed to reappraise whether SRS results for patients ≥75 (very elderly) differ from those of patients w
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 150
Large cell neuroendocrine carcinoma (LCNEC) is a rare pulmonary malignancy with clinicopathologic features of both non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Given the paucity of available data regarding LCNEC management, w
Autor:
Sylvie Friard, Marie-Ange Massiani, Christos Chouaid, Hélène Doubre, Anne-cecile Metivier, Leila Zemoura, Laure Tabèze, Marie Mayenga, Céline Callens, Elisabeth Longchampt, Jean-Baptiste Assié, Samia Melaabi, Isabelle Monnet, Séverine Fraboulet, Louis-Jean Couderc
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 150
About 2-3% of non-small-cell lung cancers (NSCLCs) harbor MET exon-14-skipping (METex14) mutations. Efficacy of the MET-inhibitor crizotinib has been reported, but progression-free survival (PFS) was very short. Immune-checkpoint inhibitors (ICIs) ha